These data illustrate that glutarate can enhance CD8+ T cell cytotoxicity, and that in vivo treatment of tumour-bearing mice with an esterified form of glutarate can reduce tumour growth and increase animal survival, highlighting the use of this immunometabolite as a potential cancer therapy. This evidence concerns the gene CD8A and neoplasm.